论文部分内容阅读
已报告,用重组白细胞介素2(rIL-2)进行大剂量静脉注射的过继免疫疗法,可使相当一部分癌患者的肿瘤缩小,但可引起严重体液潴留及增加心肺负担等副作用。为了保证这种疗法的治疗效果而又减少其副作用,作者将rIL-2大量静脉注射法改为持续注入法,使其剂量逐渐增加。本文对48例晚期癌患者,每24小时内持续注入rIL-2,为期5天,然后休息36小时,再进行为期4天的置换淋巴细胞的治疗。去除其中8例,在可评价的40例患者中,13例(32.5%)部分有效,2例轻度有效。部分有效患者有何杰金氏病(1/1)、非何杰金氏病(1/1)、肺癌(1/5)、卵巢癌(1/1)、颌下腺癌
It has been reported that adoptive immunotherapy with high-dose intravenous injection of recombinant interleukin 2 (rIL-2) can reduce the tumor size in a large proportion of cancer patients, but it can cause serious side effects such as fluid retention and increased heart and lung burden. In order to ensure the therapeutic effect of this therapy and reduce its side effects, the author changed the rIL-2 from a large number of intravenous injection method to continuous injection method, so that the dose gradually increased. In this article, 48 patients with advanced cancer were continuously injected with rIL-2 every 24 hours for a period of 5 days and then rested for 36 hours before undergoing a 4-day replacement of lymphocytes. Eight of them were removed. Of the 40 patients that could be evaluated, 13 (32.5%) were partially effective, and 2 were mildly effective. Partially effective patients with Hodgkin’s disease (1/1), non-Hodgkin’s disease (1/1), lung cancer (1/5), ovarian cancer (1/1), submandibular gland cancer